+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Ypsomed Holding AG (YPSN) - Product Pipeline Analysis, 2024 Update

  • PDF Icon

    Company Profile

  • 45 Pages
  • August 2024
  • GlobalData
  • ID: 5655747
Description Jump to:
Ypsomed Holding AG (Ypsomed) is a medical device company. It designs, develops and manufactures injection and infusion systems for self-medication and offers related services. The company's products find application in the treatment of diabetes, infertility, growth disorders and various other clinical indications. Ypsomed's product portfolio includes autoinjectors, dual chamber pens, and pen injectors. The company also provides services ranging from design and development projects, flexible prototyping, human factors engineering, monitoring services, therapy management and IP landscape management to manufacturing and assembly infrastructure and registration support. Ypsomed offers solutions to physicians, and pharmaceutical and biotechnology companies. The company has operations in Switzerland, Europe and North America among others. Ypsomed is headquartered in Burgdorf, Switzerland.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Ypsomed Holding AG
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.

Reasons to Buy:

  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

  • Ypsomed Holding AG Company Overview
  • Ypsomed Holding AG Company Snapshot
  • Ypsomed Holding AG Pipeline Products and Ongoing Clinical Trials Overview
  • Ypsomed Holding AG - Pipeline Analysis Overview
  • Business Description
  • Ypsomed Holding AG - Key Facts
  • Ypsomed Holding AG - Major Products and Services
  • Ypsomed Holding AG Pipeline Products by Development Stage
  • Ypsomed Holding AG Ongoing Clinical Trials by Trial Status
  • Ypsomed Holding AG Pipeline Products Overview
  • mylife Loop
  • mylife Loop Product Overview
  • mylife Loop Clinical Trial
  • mylife YpsoPump
  • mylife YpsoPump Product Overview
  • mylife YpsoPump Clinical Trial
  • mylife YpsoPump 2.0 With Integrated CGM
  • mylife YpsoPump 2.0 With Integrated CGM Product Overview
  • Servopen Zero
  • Servopen Zero Product Overview
  • Smartpilot Zero
  • Smartpilot Zero Product Overview
  • UnoPen Zero
  • UnoPen Zero Product Overview
  • YpsoDose
  • YpsoDose Product Overview
  • YpsoDose Zero
  • YpsoDose Zero Product Overview
  • YpsoMate Zero 2.25 Pro
  • YpsoMate Zero 2.25 Pro Product Overview
  • YpsoMate Zero On
  • YpsoMate Zero On Product Overview
  • YpsoPod
  • YpsoPod Product Overview
  • Ypsomed Holding AG - Key Competitors
  • Ypsomed Holding AG - Key Employees
  • Ypsomed Holding AG - Key Employee Biographies
  • Ypsomed Holding AG - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Recent Developments
  • Ypsomed Holding AG, Recent Developments
  • Aug 13, 2024: Astria Therapeutics taps Ypsomed’s autoinjector for hereditary angioedema drug delivery
  • Jun 12, 2024: medac Chooses Ypsomed Autoinjector
  • Oct 26, 2023: Viridian Therapeutics Enters Autoinjector Pen Device Customization and Supply Agreement with Ypsomed AG for Subcutaneous Drug Delivery in Thyroid Eye Disease
  • Oct 12, 2023: Mylife Loop Improves Health of Pregnant Women With Type 1 Diabetes and Their Babies
  • Oct 06, 2023: Ypsomed Enhances Self-Injection Device Platforms With Integrated Human Factors Services
  • Sep 20, 2023: Ypsomed Concludes a Long-Term Supply Agreement for Large Quantities of Autoinjectors
  • Jun 07, 2023: Ypsomed Partners With S3 Connected Health to Expand Its Digital Health Offering
  • May 09, 2023: Ypsomed expands production facility in Schwerin
  • Dec 21, 2022: Abbott's FreeStyle Libre 3 Integrated with Automated Insulin Delivery System mylife Loop in Germany
  • Dec 07, 2022: Ypsomed and CamDiab launch the first system for automated insulin dosing with Abbott’s FreeStyle Libre 3
  • Appendix
  • Methodology
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Ypsomed Holding AG Pipeline Products and Ongoing Clinical Trials Overview
  • Ypsomed Holding AG Pipeline Products by Equipment Type
  • Ypsomed Holding AG Pipeline Products by Indication
  • Ypsomed Holding AG Ongoing Clinical Trials by Trial Status
  • Ypsomed Holding AG, Key Facts
  • Ypsomed Holding AG, Major Products and Services
  • Ypsomed Holding AG Number of Pipeline Products by Development Stage
  • Ypsomed Holding AG Pipeline Products Summary by Development Stage
  • Ypsomed Holding AG Ongoing Clinical Trials by Trial Status
  • Ypsomed Holding AG Ongoing Clinical Trials Summary
  • mylife Loop - Product Status
  • mylife Loop - Product Description
  • mylife Loop - Randomised Open Label Clinical Trial Examining the Safety and Efficacy of the Android Artificial Pancreas System (AAPS) With Advanced Bolus-Free Features in Adults With Type 1 Diabetes: Extension Trial Using Ultra-Fast Acting Insulin
  • mylife Loop - Randomized Open Label Clinical Trial Examining the Safety and Efficacy of the Android Artificial Pancreas System (AAPS) with Advanced Bolus-free Features in Adults with Type 1 Diabetes
  • mylife YpsoPump - Product Status
  • mylife YpsoPump - Product Description
  • mylife YpsoPump - An Open-label, Multi-center, Randomized, Two Arm Single Period Parallel Study to Assess the Efficacy, Safety and Utility of Hybrid Closed-loop Glucose Control Compared to Standard Insulin Therapy Combined with Continuous Glucose Monitoring in Young People (Greater Than or Equal to 16 Years) and Adults with Cystic Fibrosis Related Diabetes (Cl4p-cf Study)
  • mylife YpsoPump - Feasibility of Automated Insulin Delivery with an Interoperable Algorithm Using an Alternative Insulin Pump
  • mylife YpsoPump - First in Human Feasibility Study; Automated Insulin Delivery Utilizing the Dexcom Next Generation Algorithm in Adults with Type 1 Diabetes
  • mylife YpsoPump 2.0 With Integrated CGM - Product Status
  • mylife YpsoPump 2.0 With Integrated CGM - Product Description
  • Servopen Zero - Product Status
  • Servopen Zero - Product Description
  • Smartpilot Zero - Product Status
  • Smartpilot Zero - Product Description
  • UnoPen Zero - Product Status
  • UnoPen Zero - Product Description
  • YpsoDose - Product Status
  • YpsoDose - Product Description
  • YpsoDose Zero - Product Status
  • YpsoDose Zero - Product Description
  • YpsoMate Zero 2.25 Pro - Product Status
  • YpsoMate Zero 2.25 Pro - Product Description
  • YpsoMate Zero On - Product Status
  • YpsoMate Zero On - Product Description
  • YpsoPod - Product Status
  • YpsoPod - Product Description
  • Ypsomed Holding AG, Key Employees
  • Ypsomed Holding AG, Key Employee Biographies
  • Ypsomed Holding AG, Subsidiaries
  • Glossary
List of Figures
  • Ypsomed Holding AG Pipeline Products by Equipment Type
  • Ypsomed Holding AG Pipeline Products by Development Stage
  • Ypsomed Holding AG Ongoing Clinical Trials by Trial Status

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Johnson & Johnson
  • Eli Lilly and Co
  • Sanofi
  • F. Hoffmann-La Roche Ltd
  • Novo Nordisk AS
  • Medtronic Plc
  • Abbott Laboratories

Related Topics

Copyright © 2002-2025 Research and Markets. All Rights Reserved.